All News

Patient is in his forties; pain has been waxing, waning, worsening for 2 weeks. He has no other significant medical history. Do lab results hold clues? What's your Dx?

Women referred from obstetrics to primary care postpartum via a pilot program were more likely to attend a PCP visit than nonreferred women.

There have been 224 reported injuries as of April 15, 2024, the CDC said, but no reports of death related to the app intermittently crashing and rebooting.

A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Your daily dose of the clinical news you may have missed.

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

In average-risk individuals, the at-home ColoSense test demonstrated 93% sensitivity for detecting CRC and 45% sensitivity for detecting advanced adenomas.

AUA 2024. Neither use of alcohol nor vaping/cigarette smoking by either parent during preconception was "appreciably" linked to an incident event, new research found.

Patients with HF who received SGLT2i therapy had significant improvement in functional capacity and QOL, regardless of sex, diabetes status, or ejection fraction, report researchers.

Study participants who had a history of stroke were nearly 60% less likely to meet guideline-recommended secondary prevention goals, new research reveals.

Your daily dose of the clinical news you may have missed.

The sNDA for the brexpiprazole plus sertraline therapy is based on positive phase 2 and 3 clinical trials showing improvement in PTSD-specific scale scores.

Your daily dose of the clinical news you may have missed.

New research suggests the interval "could potentially be extended" without significant harms and could reduce unnecessary invasive procedures. , ie, missed early detection and CRC-specific mortality.

More advanced practice clinicians and fewer physicians are providing contraception services, researchers reported.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).